Time to Next Treatment in Patients with Chronic Lymphocytic Leukemia Initiating First-Line Ibrutinib or Acalabrutinib - supplementary material

Jacobs, Ryan; Lu, Xiaoxiao; Emond, Bruno; Morrison, Laura; Kinkead, Frederic; Lefebvre, Patrick; el `ene Lafeuille, Marie-H´; Khan, Wasiulla; H Wu, Linda; P Qureshi, Zaina; Yair Levy, Moshe

doi:10.25402/FON.23723679.v1

22-RWE-6327_TTNT-VisAbstract_L6-3-B_revised-1.pdf (10.2 MB)

Time to Next Treatment in Patients with Chronic Lymphocytic Leukemia Initiating First-Line Ibrutinib or Acalabrutinib - supplementary material

poster

posted on 2023-07-21, 08:44 authored by Ryan Jacobs, Xiaoxiao Lu, Bruno Emond, Laura Morrison, Frederic Kinkead, Patrick Lefebvre, Marie-H´ el `ene Lafeuille, Wasiulla Khan, Linda H Wu, Zaina P Qureshi, Moshe Yair Levy

Real-World Comparison of Time to Next Treatment for Patients With Chronic Lymphocytic Leukemia Initiated on First-line Treatment With Ibrutinib Versus Acalabrutinib - infographic